Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$375K Sell
889
-239
-21% -$95.3K 0.07% 151
2026
Q2
$408K Sell
1,128
-805
-42% -$276K 0.08% 137
2026
Q1
$680K Buy
1,933
+104
+6% +$37.1K 0.14% 94
2025
Q4
$599K Buy
1,829
+427
+30% +$135K 0.13% 96
2025
Q3
$396K Buy
1,402
+256
+22% +$74.2K 0.09% 134
2025
Q2
$320K Buy
1,146
+36
+3% +$10.2K 0.08% 126
2025
Q1
$346K Buy
1,110
+100
+10% +$29.5K 0.1% 118
2024
Q4
$263K Buy
1,010
+40
+4% +$11.9K 0.07% 128
2024
Q3
$313K Buy
970
+98
+11% +$32.1K 0.09% 119
2024
Q2
$272K Buy
+872
New +$256K 0.08% 125

Other funds holding AMGN

Crumly & Associates's AMGN Position: Q3 2026 in Review

Crumly & Associates reduced its Amgen (AMGN) stake by 21% in Q3 2026, selling an estimated $95.3K and leaving 889 shares worth $375K. The position accounts for 0.07% of the portfolio, ranked #151.

Crumly & Associates first reported a position in AMGN in Q2 2024 and has held it in 10 quarters since. The position peaked at $680K in Q1 2026. 3,271 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Crumly & Associates held 889 shares of Amgen worth $375K as of Q3 2026.
  • Crumly & Associates sold 239 Amgen shares in Q3 2026, an estimated $95.3K.
  • Amgen made up 0.07% of Crumly & Associates's portfolio in Q3 2026, its #151 holding.
  • Crumly & Associates first reported a position in Amgen in Q2 2024 and has held it in 10 quarters since.
  • Crumly & Associates's Amgen position peaked at $680K in Q1 2026.
  • 3,271 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Crumly & Associates's 13F filing for Q3 2026, filed 7 Oct 2026.